February 8, 2017 09:36 AM ESTUpdated February 10, 10:56 AM

After clearing an FDA hurdle, Amgen wins an FDA OK on CKD drug Parsabiv

Arsalan Arif

Founder

Amgen barely managed to complete a full paragraph when the pharma giant announced last August that the FDA had rejected Parsabiv (etelcalcetide) for secondary hyperparathyroidism …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After clearing an FDA hurdle, Amgen wins an FDA OK on CKD drug Parsabiv

Arsalan Arif

Founder

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Pharma's wins and losses in Trump's sprawling executive order on drug prices

Biotech seed rounds sink to lowest level in years as industry slump drags on

Exclusive: A small biotech will bring Roche's Angelman drug back to life

US drugs rely heavily on ingredients made overseas, new report shows

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Af­ter clear­ing an FDA hur­dle, Am­gen wins an FDA OK on CKD drug Parsabiv

Founder

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

After clearing an FDA hurdle, Amgen wins an FDA OK on CKD drug Parsabiv